Paul Scigalla
About Paul Scigalla
Paul Scigalla, M.D., Ph.D., is Genelux’s Chief Medical Officer (CMO), serving in this role since September 2011. He is 80 years old as of the 2025 proxy and holds both an M.D. and Ph.D. in pediatrics from Humboldt University in Berlin . Prior roles include senior drug development and oncology leadership positions at Boehringer Mannheim, SUGEN, and Pharmacia/Pfizer, and he has concurrently led International Pharmaceutical Research Consulting since 2003 . No company-level TSR, revenue, or EBITDA growth targets tied to his pay are disclosed for Dr. Scigalla; the company’s program emphasizes discretionary cash bonuses and equity awards (primarily options, with RSUs introduced more broadly in 2024 for NEOs) .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Boehringer Mannheim | SVP, Development Worldwide | 1984–1998 | Led global development; late-stage clinical execution and portfolio development |
| SUGEN, Inc. | Executive Vice President | 1998–2001 | Oncology pipeline leadership; development oversight |
| Pharmacia/Pfizer (Bedminster, NJ) | Vice President, Research Oncology | 2001–2003 | Oncology R&D leadership; translational research |
| International Pharmaceutical Research Consulting | President & CEO | 2003–present | Independent research consulting and strategic development advisory |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| International Pharmaceutical Research Consulting | President & CEO | 2003–present | Ongoing external leadership concurrent with CMO role |
Fixed Compensation
- Dr. Scigalla was not a named executive officer (NEO) in 2023, 2024, or 2025; therefore, detailed salary/bonus disclosures for him are not in the Summary Compensation Tables (NEOs were CEO/CFO/Head of Quality for 2023, and CEO/CFO/CTO for 2024) .
- Company program design: base salary plus annual discretionary bonus; NEOs eligible for annual discretionary equity (options and/or RSUs) under the 2022 Plan; RSUs introduced for NEOs in December 2024 .
Performance Compensation
- The company primarily uses stock options and, more recently for NEOs, RSUs; awards are granted at or above fair market value and generally vest time-based over two to four years, with potential acceleration tied to termination/change-in-control events per plan/award terms .
- The 2023 Inducement Plan specifies that awards do not automatically accelerate upon change in control unless provided in the award agreement .
Equity Ownership & Alignment
Beneficial Ownership Snapshot (Options Exercisable within 60 days)
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Options exercisable within 60 days (#) | 163,883 | 163,883 | 149,994 |
Option Grants Subject to September 2022 Repricing
| Grant Date | Number of Option Shares | Pre-Repricing Exercise Price | Post-Repricing Exercise Price |
|---|---|---|---|
| 11/4/2014 | 30,555 | $9.00 | $6.00 |
| 5/1/2015 | 16,666 | $9.00 | $6.00 |
| 12/31/2016 | 16,666 | $9.00 | $6.00 |
| 3/17/2017 | 16,666 | $9.00 | $6.00 |
| 12/31/2017 | 16,666 | $10.50 | $6.00 |
| 12/31/2018 | 16,666 | $9.00 | $6.00 |
| 12/31/2019 | 16,666 | $9.00 | $6.00 |
| 9/24/2020 | 16,666 | $9.00 | $6.00 |
| 9/8/2022 | 16,666 | $10.50 | $6.00 |
Insider Transactions Indicator
| Filing Date | Transaction Date | Form Type | Reported Shares | Description |
|---|---|---|---|---|
| Oct 21, 2024 | Oct 18, 2024 | Form 4 | 33,330 | Filed Form 4 reporting a grant; company IR archive provides filing; Benzinga summary lists 33.33K grant |
Alignment Policies and Protections
- Hedging and pledging prohibited: insiders may not engage in short sales, options/hedging, or margin/pledging of company stock .
- Indemnification agreements are in place with each director and executive officer .
- Related party transactions policy requires Audit Committee/Board approval for items ≥$120K (or 1% of average total assets); since Jan 1, 2023, none disclosed involving executive officers beyond compensation/plan arrangements .
Employment Terms
- Executive officers serve at the discretion of the Board; no Paul-specific employment agreement, severance, or change-in-control economics are disclosed in the proxies reviewed .
- Plan mechanics: awards under the 2023 Inducement Plan do not auto-accelerate on change in control; acceleration may be provided in award agreements .
Investment Implications
- Pay-for-performance alignment is primarily through stock options; however, the September 2022 option repricing to $6.00 reduced strike prices on previously underwater awards (including Dr. Scigalla’s grants), which can weaken performance linkage and is a governance red flag to monitor .
- Insider policy banning hedging/pledging is strong for alignment, reducing collateralization/forced sale risks .
- With 149,994 options exercisable within 60 days as of mid-2025 vs. 163,883 in prior years, potential future exercises represent supply considerations; monitor subsequent Form 4 filings for vesting/exercise-driven selling pressure .
- No disclosed severance/CIC cash protections specific to Dr. Scigalla; focus analysis on award terms and plan-level change-in-control treatment in his grant agreements if/when available .
- Tenure and deep oncology development background support execution capability; investors should evaluate succession planning given disclosed age and the company’s evolving equity mix (RSUs appear more common for NEOs since late 2024) .